AstraZeneca plc

07/01/2024 | Press release | Distributed by Public on 07/01/2024 01:21

Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.